Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

468 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-Term Outcomes in IgA Nephropathy.
Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, Steenkamp R, Wong K, Turner AN, Wang K, Gale DP, Barratt J. Pitcher D, et al. Among authors: mercer a. Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738. doi: 10.2215/CJN.0000000000000135. Epub 2023 Apr 13. Clin J Am Soc Nephrol. 2023. PMID: 37055195 Free PMC article.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Among authors: mercer a. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Barratt J, Rovin B, Wong MG, Alpers CE, Bieler S, He P, Inrig J, Komers R, Heerspink HJL, Mercer A, Noronha IL, Radhakrishnan J, Rheault MN, Rote W, Trachtman H, Trimarchi H, Perkovic V; PROTECT investigators. Barratt J, et al. Among authors: mercer a. Kidney Int Rep. 2023 Mar 4;8(5):1043-1056. doi: 10.1016/j.ekir.2023.02.1086. eCollection 2023 May. Kidney Int Rep. 2023. PMID: 37180506 Free PMC article.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. Among authors: mercer a. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: mercer a. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Trachtman H, Radhakrishnan J, Rheault MN, Alpers CE, Barratt J, Heerspink HJL, Noronha IL, Perkovic V, Rovin B, Trimarchi H, Wong MG, Mercer A, Inrig J, Rote W, Murphy E, Bedard PW, Roth S, Bieler S, Komers R. Trachtman H, et al. Among authors: mercer a. Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032. eCollection 2024 Apr. Kidney Int Rep. 2024. PMID: 38765567 Free PMC article.
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.
Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M, Eckardt KU, Kramann R, Moeller MJ, Floege J; GCKD study investigators. Stamellou E, et al. Among authors: mercer a. Clin Kidney J. 2024 Apr 27;17(7):sfae131. doi: 10.1093/ckj/sfae131. eCollection 2024 Jul. Clin Kidney J. 2024. PMID: 38989280 Free PMC article.
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.
Stamellou E, Nadal J, Hendry B, Mercer A, Seikrit C, Bechtel-Walz W, Schmid M, Moeller MJ, Schiffer M, Eckardt KU, Kramann R, Floege J; GCKD study investigators. Stamellou E, et al. Among authors: mercer a. Clin Kidney J. 2024 Jul 22;17(8):sfae230. doi: 10.1093/ckj/sfae230. eCollection 2024 Aug. Clin Kidney J. 2024. PMID: 39149090 Free PMC article.
Community-based reconstruction and simulation of a full-scale model of the rat hippocampus CA1 region.
Romani A, Antonietti A, Bella D, Budd J, Giacalone E, Kurban K, Sáray S, Abdellah M, Arnaudon A, Boci E, Colangelo C, Courcol JD, Delemontex T, Ecker A, Falck J, Favreau C, Gevaert M, Hernando JB, Herttuainen J, Ivaska G, Kanari L, Kaufmann AK, King JG, Kumbhar P, Lange S, Lu H, Lupascu CA, Migliore R, Petitjean F, Planas J, Rai P, Ramaswamy S, Reimann MW, Riquelme JL, Román Guerrero N, Shi Y, Sood V, Sy MF, Van Geit W, Vanherpe L, Freund TF, Mercer A, Muller E, Schürmann F, Thomson AM, Migliore M, Káli S, Markram H. Romani A, et al. Among authors: mercer a. PLoS Biol. 2024 Nov 5;22(11):e3002861. doi: 10.1371/journal.pbio.3002861. eCollection 2024 Nov. PLoS Biol. 2024. PMID: 39499732 Free PMC article.
468 results